NGM BIOPHARMACEUTICALS INC
NGM BIOPHARMACEUTICALS INC (NGM): 10 pipeline candidates · ~19 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
19.2 months
D/E 0.14 · 0% dilution
Lead: Phase 2/Phase 3
10 candidates
N/A
N/A
A transparent, data-derived signal for NGM BIOPHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$61.3M
Quarterly Burn
$23.0M
Runway
19.2 mo
Revenue
$165K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| aldafermin | Phase 2/Phase 3 |
| ngm120 | Phase 1/Phase 2 |
| ngm120 100mg q3w | Phase 1/Phase 2 |
| ngm120 q4w | Phase 2 |
| ngm120 q8w | Phase 2 |
| ngm282 | Phase 2 |
| ngm438 | Phase 1 |
| ngm621 | Phase 2 |
| ngm707 | Phase 2 |
| ngm831 | Phase 1 |
Frequently asked questions
How many drug candidates are in NGM BIOPHARMACEUTICALS INC's pipeline?
NGM BIOPHARMACEUTICALS INC (NGM) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NGM BIOPHARMACEUTICALS INC's lead drug candidate?
NGM BIOPHARMACEUTICALS INC's most advanced tracked candidate is aldafermin (Phase 2/Phase 3) for Primary Sclerosing Cholangitis.
What is NGM BIOPHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NGM BIOPHARMACEUTICALS INC has approximately 19.2 months of cash runway.
Who is the CEO of NGM BIOPHARMACEUTICALS INC?
William J. Rieflin is the chief executive officer of NGM BIOPHARMACEUTICALS INC (NGM).
Get the full picture on NGM BIOPHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.